Advertisement Pharmaceutical Business review - Page 11 of 5225 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
November 22, 2024

Dyadic receives grant from Gates Foundation for RSV antibody development

Dyadic International has received a $3m grant from the Bill & Melinda Gates Foundation to develop monoclonal antibodies (mAbs) for the treatment of respiratory syncytial virus (RSV) and malaria.

The $3m grant is to develop monoclonal antibodies for treatment of respiratory syncytial virus and malaria. Credit: National Institute of Allergy and Infectious Diseases on Unsplash.